FAQ : Reporting for Healthcare Professionals

User Rating: 1 / 5

Star ActiveStar InactiveStar InactiveStar InactiveStar Inactive

1) What is the scope of ADR Monitoring?
    Reporters are encouraged to report any suspicious adverse event, especially on:
     - Newly registered drugs
     - Reactions encountered with generic products which are not commonly associated with the equivalent market leader product
     - Off-label indications
     - Doses differing from the recommended doses

2) What should not be reported?
    Reactions to food products and unprocessed herbs should not be reported as these products are beyond the jurisdiction of the DCA.

3) What to report?
    If Healthcare Professionals feel that it is cumbersome to report trivial, common and well documented adverse reactions, they should report reactions which are serious, unexpected or unlabeled to the DCA.
4) How to report?
     You can report any ADR cases using the Blue Form and send via one of these methods upon completion:
        i) Mail the hardcopy to:
             Pusat Pemonitoran Kesan Advers Ubat Kebangsaan
             Biro PengawalanFarmaseutikalKebangsaan
             PetiSurat 319, Jalan Sultan,
             46730 Petaling Jaya,
        ii) Fax to 03-79567151
       iii) Online submission via www.bpfk.gov.my
       iv) The Blue Form is available in NPCB website, www.bpfk.gov.my

5) Basic principles of efficient reporting.
      i) Report the event soon after it occurs.
      ii) Report whilst the patient is still with you.
      iii) Ask the patient particularly about other products taken.
      iv) If any additional data is available later, send in a supplementary note.
      v) In cases where a foetus or suckling infant sustains an ADR, information of both the parent and the child/fetus should be provided.
     vi) Always write legibly.
     vii) All reports must have minimum the following four data elements:
           a) An identifiable patient
           b) An identifiable reporter
           c) A suspected drug
           d) An adverse event

6) Is there any guideline available for ADR reporting and monitoring?
     The Malaysian Guidelines for the Reporting & Monitoring is available in NPCB website.


National Pharmaceutical Regulatory Agency (NPRA)

Lot 36, Jalan Universiti (Jalan Prof Diraja Ungku Aziz), 46200 Petaling Jaya, Selangor, Malaysia.

  • Phone: +603-7883 5400




The Government of Malaysia and the National Pharmaceutical Regulatory Agency are not responsible for any loss or damage caused by the usage of any information obtained from this website.

Mobile Web :

Site Last Modified

  • Last Modified: Saturday 20 July 2024, 01:25:04.
© Copyright 2023 . All Rights Reserved National Pharmaceutical Regulatory Agency NPRA


Main Menu English